Dmitry Balyasny’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dmitry Balyasny’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,100	Closed	-$541K	–	2921
2025 Q4	$541K	Buy	+9,100	New	+$495K	﹤0.01%	2488
2024 Q4	–	Sell	-50,000	Closed	-$3.51M	–	2753
2024 Q3	$3.51M	Buy	50,000 +29,700	+146%	+$2.48M	0.01%	1425
2024 Q2	$1.67M	Buy	+20,300	New	+$1.69M	﹤0.01%	1591
2024 Q1	–	Sell	-100,000	Closed	-$9.64M	–	2630
2023 Q4	$9.64M	Buy	+100,000	New	+$8.85M	0.02%	881
2021 Q1	–	Sell	-53,000	Closed	-$4.65M	–	1768
2020 Q4	$4.65M	Buy	+53,000	New	+$4.2M	0.03%	673
2020 Q3	–	Sell	-100,000	Closed	-$12.3M	–	1302
2020 Q2	$12.3M	Buy	+100,000	New	+$9.94M	0.11%	291
2019 Q4	–	Sell	-50,000	Closed	-$3.37M	–	1169
2019 Q3	$3.37M	Hold	50,000	–	–	0.02%	624
2019 Q2	$4.4M	Buy	+50,000	New	+$4.28M	0.03%	646
2018 Q3	–	Sell	-368,700	Closed	-$34.7M	–	1680
2018 Q2	$34.7M	Buy	+368,700	New	+$32.3M	0.16%	175

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dmitry Balyasny's BMRN Position: Q2 2026 in Review

Dmitry Balyasny reduced its BioMarin Pharmaceuticals (BMRN) stake by 23% in Q2 2026, selling an estimated $16.9M and leaving 1,054,613 shares worth $60.3M. The position accounts for 0.08% of the portfolio, ranked #312.

Dmitry Balyasny first reported a position in BMRN in Q2 2014 and has held it in 42 quarters since. The position peaked at $156M in Q4 2017. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Dmitry Balyasny held 1,054,613 shares of BioMarin Pharmaceuticals worth $60.3M as of Q2 2026.
Dmitry Balyasny sold 308,139 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
BioMarin Pharmaceuticals made up 0.08% of Dmitry Balyasny's portfolio in Q2 2026, its #312 holding.
Dmitry Balyasny first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
Dmitry Balyasny's BioMarin Pharmaceuticals position peaked at $156M in Q4 2017.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.